🇺🇸 FDA
Pipeline program

KL003 cell injection Drug Product

IIT2023021

Unknown gene_therapy active

Quick answer

KL003 cell injection Drug Product for Transfusion-dependent Beta-Thalassemia is a Unknown program (gene_therapy) at China SXT Pharmaceuticals with 1 ClinicalTrials.gov record(s).

Program details

Company
China SXT Pharmaceuticals
Indication
Transfusion-dependent Beta-Thalassemia
Phase
Unknown
Modality
gene_therapy
Status
active

Clinical trials